Literature DB >> 12481673

Neonatal sepsis: high antibiotic resistance of the bacterial pathogens in a neonatal intensive care unit in Karachi.

A Mahmood1, K A Karamat, T Butt.   

Abstract

OBJECTIVE: To study the bacterial pathogens causing neonatal sepsis and their sensitivity pattern so that guidelines can be prepared for empirical antibiotic therapy.
SETTING: The study was conducted in the neonatal intensive care unit (NICU) at PNS Shifa (Naval Hospital), Karachi during January 1997 to June 1999.
METHODS: Blood specimens for culture were drawn from 520 newborns admitted in a NICU with sepsis. The specimens were inoculated into brain heart infusion broth. Subcultures were performed on days 1, 2, 3, 5, 7 and 10. The isolates were identified by standard biochemical tests. Antibiotic resistance pattern of the isolates was studied by Modified Kirby Baur disc diffusion technique.
RESULTS: A total of 212 organisms were isolated. These included Staphylococcus aureus (n = 65), Klebsiella pneumoniae (n = 73), Acinetobacter baumannii (n = 23), Escherichia coli (n = 22), Enterobacter cloacae (n = 18), Citrobacter diversus (n = 5), Pseudomonas aeruginosa (n = 4) and group B Streptococcus (n = 2). On antibiotic sensitivity testing, 61.54% of Staphylococcus aureus isolates were found to be methicillin resistant. Susceptibility to the other common drugs was also quite low while 89.23% of these were susceptible to amikacin and 100% to vancomycin. More than 90% gram negative rods were resistant to ampicillin and co-trimoxazole. Resistance to gentamicin was as high as 90.4% for Klebsiella pneumoniae; 60.87% for Acinetobacter baumannii. Resistance to the third generation cephalosporins and the quinolone tested (ciprofloxacin) varied between 25-75%. Majority of the isolates were susceptible to meropenem and amikacin.
CONCLUSION: In view of the isolation of highly antibiotic resistant organisms, vancomycin in combination with amikacin or a carbapenem is the drug of choice for empirically treating neonatal sepsis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12481673

Source DB:  PubMed          Journal:  J Pak Med Assoc        ISSN: 0030-9982            Impact factor:   0.781


  8 in total

1.  Early-onset sepsis in a neonatal intensive care unit in Beni Suef, Egypt: bacterial isolates and antibiotic resistance pattern.

Authors:  Sameh Samir Fahmey
Journal:  Korean J Pediatr       Date:  2013-08-27

2.  Validity of C-reactive protein (CRP) for diagnosis of neonatal sepsis.

Authors:  Effat Hisamuddin; Aliya Hisam; Sughra Wahid; Ghulam Raza
Journal:  Pak J Med Sci       Date:  2015       Impact factor: 1.088

3.  Neonatal sepsis: high antibiotic resistance of the bacterial pathogens in a neonatal intensive care unit of a tertiary care hospital.

Authors:  Arpita Jigar Shah; Summaiya A Mulla; Sangita B Revdiwala
Journal:  J Clin Neonatol       Date:  2012-04

4.  Detection of AmpC β-lactamase producing bacteria isolated in neonatal sepsis.

Authors:  Sonia Salamat; Hasan Ejaz; Aizza Zafar; Humera Javed
Journal:  Pak J Med Sci       Date:  2016 Nov-Dec       Impact factor: 1.088

Review 5.  Amikacin: Uses, Resistance, and Prospects for Inhibition.

Authors:  Maria S Ramirez; Marcelo E Tolmasky
Journal:  Molecules       Date:  2017-12-19       Impact factor: 4.411

6.  Emerging antimicrobial resistance in early and late-onset neonatal sepsis.

Authors:  Lamiaa Mohsen; Nermin Ramy; Dalia Saied; Dina Akmal; Niveen Salama; Mona M Abdel Haleim; Hany Aly
Journal:  Antimicrob Resist Infect Control       Date:  2017-06-13       Impact factor: 4.887

7.  Bacteriological profile and antibiotic susceptibility of neonatal sepsis in neonatal intensive care unit of a tertiary hospital in Nepal.

Authors:  Bhishma Pokhrel; Tapendra Koirala; Ganesh Shah; Suchita Joshi; Pinky Baral
Journal:  BMC Pediatr       Date:  2018-06-27       Impact factor: 2.125

8.  Antibiotic Resistance Patterns of Bacterial Isolates from Neonatal Sepsis Patients at University Hospital of Leipzig, Germany.

Authors:  Belay Tessema; Norman Lippmann; Matthias Knüpfer; Ulrich Sack; Brigitte König
Journal:  Antibiotics (Basel)       Date:  2021-03-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.